AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...
U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...
AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. | After several quarters of creeping up on Humira, ...
Hosted on MSN12d
AbbVie signs agreement to acquire Aliada for $1.4bnAbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a $1.4bn cash deal. The ...
EDT AbbVie (ABBV) says ‘pleased’ with progress advancing product pipeline Published first on TheFly – the ultimate ...
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Chris Schott ...
AbbVie on Thursday said EvolveImmune will receive $65 million in upfront fees and an equity investment under the agreement and will be eligible for up to $1.4 billion in option fees and milestones, ...
a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily ... of a development liability associated with a previously divested product. Intangible asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback